Evidence map›Paper›PMID 42534594›Full record

ReviewEClinicalMedicine2026

Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges.

Esteban Ciliberti, Marta Nerone, Vincenza Ricco, Hui-Ming Lin, Frederik Marmé, Cristiana Sessa, Isabelle Ray Coquard, Kathleen N Moore, Ilaria Colombo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Esteban CilibertiMedical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.
Marta NeroneMedical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.
Vincenza RiccoMedical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.
Hui-Ming LinMedical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.
Frederik MarméMedical Faculty Mannheim, Heidelberg University, University Hospital Mannheim, Department of Gynecologic Oncology, 68167, Mannheim, Germany.
Cristiana SessaMedical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.
Isabelle Ray CoquardCentre Léon Bérard, Medical Oncology, Lyon, France.
Kathleen N MooreBuffett Cancer Center at the University of Nebraska, Omaha, NE, USA.
Ilaria ColomboMedical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-drug conjugates (ADCs), which are tumor-targeting antibodies conjugated with cytotoxic chemotherapy agents, have emerged as a promising therapeutic approach in gynaecological cancers. Gynaecologicaal tumor-associated antigens targeted by ADCs include folate receptor-α (FRα), HER2, TROP2, tissue factor (TF), CDH6, CLDN6, B7-H4, B7-H3 and NaPi2b. Currently, three ADCs are clinically available for the treatment of gynaecological cancers: Mirvetuximab soravtansine for FRα-positive ovarian cancer, Tisotumab vedotin (targeting TF) for cervical cancer, and Trastuzumab deruxtecan for HER2-positive solid tumors. Various stages of investigation of ADCs as single agent or in combination treatments are ongoing with promising early signs of efficacy. Upon positive results from phase III trials, new treatment options will be available to reshape the standard of care of gynaecological malignancies and improve patients' outcome. This review summarizes the major clinical studies of ADCs in ovarian, endometrial and cervical cancer, and explores the main challenges related to their use in clinical practice.

Indexed as

Antibody drug conjugateCervical cancerEndometrial cancerGynaecological cancersOvarian cancer

Identifiers

PMID42534594
PMCPMC13420614

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.